Navigation Links
Human Gene Therapy expands with robust new methods journal
Date:9/13/2011

New Rochelle, NY, September 13, 2011Mary Ann Liebert, Inc. announces the launch of a journal expansion, Human Gene Therapy Methods, to complement the flagship publication Human Gene Therapy. HGT Methods, which is officially Part B of Human Gene Therapy, is dedicated to publishing technological advances in cell and gene therapy that promote the development of gene therapy products into successful therapeutics. While Methods has always been a key element of the flagship journal, HGT Methods breaks new ground as the first publication to exclusively focus on the applications of gene therapy to product testing and development. HGT Methods will publish bimonthly and will premier in January 2012, with accepted articles appearing online ahead of print beginning in November 2011. Editor-in-Chief, James M. Wilson, MD, PhD, introduces this exciting journal expansion in this month's Editorial.

The field of gene therapy is rapidly evolving and holds great promise for its applications to treating human diseases, yet no product has been commercialized. Better methods are needed to evaluate the outcome of gene transfer technologies which are just entering the clinic. Likewise, standards for producing and characterizing products for distribution to patients have yet to be determined. HGT Methods answers the growing need for a central forum for nurturing, promoting, and advancing new technologies and methods that will ultimately pave the way for product development.

The existing leadership team of Human Gene Therapy, together with the newly appointed HGT Methods Editor, Thierry Vanden Driessche, PhD, will be responsible for the development and management of this new Journal.

"Gene therapy was predicted to revolutionize the practice of medicine," according to James M. Wilson, MD, PhD, Editor-in-Chief and Director of the Gene Therapy Program, Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia. "After 30 years of research and recent successes in Phase I clinical trials, it appears the revolution is upon us. For this revolution to realize its true potential we need to translate proof-of-concept studies in small human trials to commercialized products that become standard clinical practice. Human Gene Therapy Methods will be the venue for publishing the technological advances necessary for gene therapy products to be developed as successful therapeutics."


'/>"/>

Contact: Vicki Cohn
vcohn@liebertpub.com
914-740-2100
Mary Ann Liebert, Inc./Genetic Engineering News
Source:Eurekalert  

Related biology news :

1. Swiss Institute of Bioinformatics celebrates 10th birthday by presenting major gifts to human health
2. Scientists identify novel inhibitor of human microRNA
3. During exercise, the human brain shifts into high gear on alternative energy
4. Complete Genomics launches, becomes worlds first large-scale human genome sequencing company
5. Research shows Brazilian acai berry antioxidants absorbed by human body
6. Study: Bird diversity lessens human exposure to West Nile Virus
7. Human Microbiome Project awards funds for technology development, data analysis and ethical research
8. TheVisualMD.com launches new animated 3-D views of human body in action
9. Gene with probable role in human susceptibility to pulmonary tuberculosis identified
10. The American Society of Human Genetics hosts 58th Annual Meeting in Philadelphia
11. Genetic based human diseases are an ancient evolutionary legacy
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Human Gene Therapy expands with robust new methods journal
(Date:6/7/2016)...  Syngrafii Inc. and San Antonio Credit Union ... integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution into ... result in greater convenience for SACU members and ... existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/2/2016)... , June 2, 2016   The Weather Company , ... Watson Ads, an industry-first capability in which consumers will be ... able to ask questions via voice or text and receive ... Marketers have long sought an advertising ... that can be personal, relevant and valuable; and can scale ...
(Date:5/24/2016)... Ampronix facilitates superior patient care by providing unparalleled technology to leaders of ... the latest premium product recently added to the range of products distributed by Ampronix. ... ... ... Medical Display- Ampronix News ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with ... in this eBook by providing practical tips, tools, and strategies for clinical researchers. ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
Breaking Biology Technology: